Tag: Bright Minds Biosciences - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Post published:November 30, 2021
Post category:Press Release

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Post published:November 3, 2021
Post category:Press Release

Bright Minds Biosciences Provides Scientific Update

Bright Minds Biosciences Provides Scientific Update

Post published:September 22, 2021
Post category:Press Release

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

Post published:August 18, 2021
Post category:Press Release

Bright Minds Biosciences Announces Application to List on Nasdaq

Bright Minds Biosciences Announces Application to List on Nasdaq

Post published:June 16, 2021
Post category:Press Release

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Post published:May 17, 2021
Post category:Press Release

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

Post published:April 27, 2021
Post category:Press Release

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Post published:March 17, 2021
Post category:Press Release

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

Post published:March 15, 2021
Post category:Press Release

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

Post published:March 3, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.